Drug Approval | October 15, 2024
Lyka’s patent pending Drug Pregabalin Gel 8% w/w receives approval from CDSCO
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
India has taken the lead in recognising NAFLD as a major non-communicable disease
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
Subscribe To Our Newsletter & Stay Updated
